GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AIM ImmunoTech Inc (STU:HXB2) » Definitions » Shiller PE Ratio

AIM ImmunoTech (STU:HXB2) Shiller PE Ratio : (As of May. 24, 2024)


View and export this data going back to . Start your Free Trial

What is AIM ImmunoTech Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


AIM ImmunoTech Shiller PE Ratio Historical Data

The historical data trend for AIM ImmunoTech's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AIM ImmunoTech Shiller PE Ratio Chart

AIM ImmunoTech Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

AIM ImmunoTech Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of AIM ImmunoTech's Shiller PE Ratio

For the Biotechnology subindustry, AIM ImmunoTech's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AIM ImmunoTech's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AIM ImmunoTech's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where AIM ImmunoTech's Shiller PE Ratio falls into.



AIM ImmunoTech Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

AIM ImmunoTech's E10 for the quarter that ended in Mar. 2024 is calculated as:

For example, AIM ImmunoTech's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.11/131.7762*131.7762
=-0.110

Current CPI (Mar. 2024) = 131.7762.

AIM ImmunoTech Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201406 -11.658 100.560 -15.277
201409 -8.195 100.428 -10.753
201412 -9.635 99.070 -12.816
201503 -9.758 99.621 -12.908
201506 -9.409 100.684 -12.315
201509 -7.057 100.392 -9.263
201512 -6.059 99.792 -8.001
201603 -3.951 100.470 -5.182
201606 -2.350 101.688 -3.045
201609 -5.097 101.861 -6.594
201612 -1.668 101.863 -2.158
201703 -4.525 102.862 -5.797
201706 -3.133 103.349 -3.995
201709 -1.477 104.136 -1.869
201712 -2.231 104.011 -2.827
201803 -2.498 105.290 -3.126
201806 -2.037 106.317 -2.525
201809 -2.460 106.507 -3.044
201812 -1.160 105.998 -1.442
201903 -2.575 107.251 -3.164
201906 -0.947 108.070 -1.155
201909 -1.026 108.329 -1.248
201912 -0.092 108.420 -0.112
202003 -0.199 108.902 -0.241
202006 -0.098 108.767 -0.119
202009 -0.068 109.815 -0.082
202012 -0.074 109.897 -0.089
202103 -0.067 111.754 -0.079
202106 -0.100 114.631 -0.115
202109 -0.068 115.734 -0.077
202112 -0.106 117.630 -0.119
202203 -0.073 121.301 -0.079
202206 -0.095 125.017 -0.100
202209 -0.131 125.227 -0.138
202212 -0.085 125.222 -0.089
202303 -0.075 127.348 -0.078
202306 -0.092 128.729 -0.094
202309 -0.150 129.860 -0.152
202312 -0.238 129.419 -0.242
202403 -0.110 131.776 -0.110

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


AIM ImmunoTech  (STU:HXB2) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


AIM ImmunoTech Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of AIM ImmunoTech's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


AIM ImmunoTech (STU:HXB2) Business Description

Traded in Other Exchanges
Address
2117 SW Highway 484, Ocala, FL, USA, 34473
AIM ImmunoTech Inc is an immuno-pharma company focused on research and development of therapeutics to treat immune disorders, viral and cancer diseases. AIM's flagship products include Ampligen (Rintatolimod), a drug of large macromolecular RNA molecules for cancer and viral diseases and drug Alferon N Injection for a category of STD infection. Clinical trials of Ampligen include studies of cancer patients with renal cell carcinoma, malignant melanoma, colorectal cancer, advanced recurrent ovarian cancer and triple negative metastatic breast cancer. The company is also advancing Ampligen as a potential treatment for COVID-19. FDA has authorized the first human trial assessing the safety and effectiveness of Ampligen in combination with interferon alfa-2b, in cancer patients with COVID-19.

AIM ImmunoTech (STU:HXB2) Headlines

No Headlines